CAS: 1392136-43-4
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | Verdinexor (KPT-335) REF: IN-DA009ZW8CAS: 1392136-43-4 | 98% | To inquire | Thu 02 Jan 25 |
 | Verdinexor REF: TM-T6123CAS: 1392136-43-4 | 98% - 99.93% | 36.00 €~1,201.00 € | Thu 02 Jan 25 |
 | Verdinexor REF: 3D-FV175276CAS: 1392136-43-4 | Min. 95% | - - - | Discontinued product |
Verdinexor (KPT-335)
CAS:1392136-43-4
Formula:
C18H12F6N6O
Purity:
98%
Color and Shape:
Solid
Molecular weight:
442.3179
Ref: IN-DA009ZW8
| 10mg | 131.00 € | ||
| 25mg | 165.00 € | ||
| 50mg | 278.00 € | ||
| 100mg | 626.00 € |
Estimated delivery in United States, on Thursday 2 Jan 2025
Verdinexor
CAS:1392136-43-4
Verdinexor (KPT-335) (KPT-335), a specific XPO1/CRM1 inhibitor, are orally bioavailable.
Formula:
C18H12F6N6O
Purity:
98% - 99.93%
Color and Shape:
Solid
Molecular weight:
442.32
Ref: TM-T6123
| 1mg | 36.00 € | ||
| 5mg | 109.00 € | ||
| 10mg | 184.00 € | ||
| 25mg | 334.00 € | ||
| 50mg | 559.00 € | ||
| 100mg | 889.00 € | ||
| 200mg | 1,201.00 € | ||
| 1mL*10mM (DMSO) | 122.00 € |
Estimated delivery in United States, on Thursday 2 Jan 2025
Verdinexor
CAS:1392136-43-4
Verdinexor is an antibody-based therapeutic that targets the fatty acid binding protein (FABP) receptor, which …
Formula:
C18H12F6N6O
Purity:
Min. 95%
Molecular weight:
442.32 g/mol
Ref: 3D-FV175276
| 50mg | Discontinued | Request information |
